Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: ex quo and quo vadimus?

In this issue of Metabolism, Omori et al [1] report that dapagliflozin, a sodium-glucose co-transporter-2 inhibitor (SGLT2i), prevents hepatic steatosis (assessed by triglyceride liver content) after 8  weeks of administration in db/db mice, a mouse model of obesity and diabetes.
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Source Type: research